Trulieve Cannabis Corp. filed an 8-K press release on November 2, 2026, announcing that the company has received federal registrations for medical marijuana dispensaries from the U.S. Drug Enforcement Administration as part of the DEA's initial issuance to qualifying state-licensed operators.

Key Highlights

  • DEA registrations received: Trulieve disclosed it has received DEA registrations for medical marijuana dispensaries as part of the DEA's initial issuance to qualifying state-licensed operators.
  • Federal framework established: According to the filing, the DEA began issuing these registrations following an Attorney General order issued in April that created a federal framework for qualifying medical marijuana businesses under the Controlled Substances Act.
  • Schedule III rescheduling: The filing states that state-licensed medical marijuana was rescheduled to Schedule III under the Controlled Substances Act, and Trulieve applied for DEA registration in April following that rescheduling.
  • Multi-state operations: The company disclosed established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia.
  • CEO statement: Chief Executive Officer Kim Rivers described the development as "another historic milestone for patients, physicians, and Trulieve," attributing it to "the bold action taken by the Trump Administration on common sense cannabis reform."

Trulieve's DEA Registration and the New Federal Cannabis Framework

According to the filing, the U.S. Drug Enforcement Administration announced it has begun the initial issuance of federal registrations to qualifying state-licensed medical marijuana dispensaries. The DEA's action, the company disclosed, represents the first phase of an Attorney General order issued in April that established a federal framework for qualifying medical marijuana businesses while maintaining federal controls under the Controlled Substances Act.

Trulieve disclosed that it applied for DEA registration for its state-licensed operations in April, following the rescheduling of state-licensed medical marijuana from its prior classification to Schedule III under the Controlled Substances Act. The company reported that it has now received those registrations as part of the DEA's initial issuance. NYSE:TRLV is listed on the New York Stock Exchange under the symbol TRLV.

In a statement included in the filing, CEO Kim Rivers characterized the development as opening "the door for clinical research while creating a level playing field for responsible operators like Trulieve." Rivers also noted the company's appreciation for "the DEA's work to advance this historic change and its continued engagement with state-licensed medical cannabis operators as the new federal framework is implemented." The filing identifies Christine Hersey, Chief Corporate Affairs and Strategy Officer, as the investor and media contact.

What Was Disclosed

Trulieve Cannabis Corp. announced via press release that it received DEA federal registrations for medical marijuana dispensaries, following the rescheduling of state-licensed medical marijuana to Schedule III and a subsequent April 2026 application by the company.